<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931875</url>
  </required_header>
  <id_info>
    <org_study_id>KY2021-052</org_study_id>
    <nct_id>NCT04931875</nct_id>
  </id_info>
  <brief_title>Total-body PET / CT in the Evaluation of Treatment and Prognosis of Lymphoma</brief_title>
  <official_title>Total-body 18F-FDG PET / CT in the Evaluation of Treatment and Prognosis of Patients With Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospective study aims to explore the value of total-body PET/CT dynamic imaging&#xD;
      (uExplorer) in assessing the treatments and prognosis in patients affected with lymphoma.&#xD;
      Total-body 18F-FDG PET/CT scans are being performed before treatment, after three cycles of&#xD;
      chemotherapy and six weeks after the end of treatment. The plan of this study involves to&#xD;
      evaluate the clinical application of total-body PET / CT in patients&#xD;
      histopathologically-diagnosed as lymphoma, and to optimize the dynamic acquisition protocols&#xD;
      with total-body 18F-FDG PET/CT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 cases of lymphoma patients are enrolled in this study. Participation in this study&#xD;
      involves three dynamic 18F-FDG PET/CT exams, which occur before the treatments start, two or&#xD;
      three days before the fourth cycle of chemotherapy, and then six weeks after the end of last&#xD;
      treatments. Progress Free Survival(PFS) and Overall Survival(OS) are used as the end points&#xD;
      to study the value of metabolic parameters obtained from the dynamic PET/CT imaging. The&#xD;
      differences of dynamic metabolic parameters and static SUV value are evaluated in patients&#xD;
      with lymphoma from the perspective of diagnosis, staging, treatment and prognosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">July 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>three years after last patient recruited</time_frame>
    <description>Progress-free survival is calculated from the date of randomization to the date of the first progress at any site or death from any cause or censored at the date of the last follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>three years after last patient recruited</time_frame>
    <description>The duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Total-body PET/CT (uExplorer)</arm_group_label>
    <description>The diagnostic value of dynamic parameters(K1、Ki etc) to evaluate the prognosis of lymphoma compared to the static ones(SUV、MTV、TLG etc).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total body PET/CT (uExplorer)</intervention_name>
    <description>A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.</description>
    <arm_group_label>Total-body PET/CT (uExplorer)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible patients with lymphoma will be scanned by total-body 18F-FDG uEXPLORER PET/CT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed, written and dated informed consent prior to any study specific&#xD;
             procedures&#xD;
&#xD;
          -  Had histologically confirmed lymphoma&#xD;
&#xD;
          -  Patients aged 18~75 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant, breast-feeding&#xD;
&#xD;
          -  Currently active second malignancy other than Lymphoma&#xD;
&#xD;
          -  Any situation not suitable for this study judged by researchers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yumei Chen, Ph.D;M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai jiaotong University School of Medicine, Renji Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai jiaotong University School of Medicine, Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chen Y, Zhou M, Liu J, Huang G. Prognostic Value of Bone Marrow FDG Uptake Pattern of PET/CT in Newly Diagnosed Diffuse Large B-cell Lymphoma. J Cancer. 2018 Mar 14;9(7):1231-1238. doi: 10.7150/jca.23714. eCollection 2018.</citation>
    <PMID>29675104</PMID>
  </reference>
  <reference>
    <citation>Zhou M, Chen Y, Liu J, Huang G. A predicting model of bone marrow malignant infiltration in (18)F-FDG PET/CT images with increased diffuse bone marrow FDG uptake. J Cancer. 2018 Apr 19;9(10):1737-1744. doi: 10.7150/jca.24836. eCollection 2018.</citation>
    <PMID>29805699</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2265-2267. doi: 10.1073/pnas.1917379117. Epub 2020 Jan 21.</citation>
    <PMID>31964808</PMID>
  </reference>
  <reference>
    <citation>Zhang YQ, Hu PC, Wu RZ, Gu YS, Chen SG, Yu HJ, Wang XQ, Song J, Shi HC. The image quality, lesion detectability, and acquisition time of (18)F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2507-2515. doi: 10.1007/s00259-020-04823-w. Epub 2020 May 18.</citation>
    <PMID>32424483</PMID>
  </reference>
  <reference>
    <citation>Zhou M, Chen Y, Huang H, Zhou X, Liu J, Huang G. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 13;7(50):83544-83553. doi: 10.18632/oncotarget.13180.</citation>
    <PMID>27835875</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Yumei Chen</investigator_full_name>
    <investigator_title>deputy head of the department of nuclear medicine</investigator_title>
  </responsible_party>
  <keyword>Lymphoma, Total-body PET/CT, Prognosis, Dynamic Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

